Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross Omisirge Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy N/A

    Omisirge (omidubicel-onlv) Coverage Criteria

    Customize your policy alerts

    Sign up for all Premera Bluecross policy alerts

    Know when Premera Bluecross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-benefit coverage and authorization for Omisirge in individuals with hematologic malignancies or severe aplastic anemia who meet specified age, transplant, donor-availability, conditioning, prescribing, and administration criteria.

    Policy Summary
    PayerPremera Bluecross
    PolicyOmisirge (omidubicel-onlv) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOctober 1, 2026
    Last ReviewApr 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior-authorization documentation confirming that the applicable medical-necessity criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage criteria were added for Omisirge (omidubicel-onlv) in adults and pediatric individuals 6 years and older with severe aplastic anemia following reduced-intensity conditioning.

    The hematologic-malignancy criteria for Omisirge were updated to remove the requirement that the individual have no history of prior allogeneic hematopoietic stem cell transplant.

    HCPCS code J3406 was added for Omisirge.

    HCPCS codes C9399 and J3590 were removed for Omisirge.

    12+Minimum age: hematologic malignancy
    6+Minimum age: severe aplastic anemia
    1 infusionDosing limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J3406Covered HCPCS code
    MedicalBenefit

    Covered and Investigational Uses

    Hematologic Malignancies

    Omisirge may be considered medically necessary for hematologic malignancies when ALL of the following criteria are met:

    Hematologic malignancy criteria

    • Age: The individual is aged 12 years or older12 years or older
    • Diagnosis and transplant plan: The individual has a diagnosis of a hematologic malignancy and is planned for umbilical cord blood transplantation following myeloablative conditioning to reduce both time to neutrophil recovery and the incidence of infection
    • Transplant candidacy: The individual is a candidate for myeloablative allogeneic hematopoietic stem cell transplantation (HSCT)
    • Required absence of exclusions

      • Donor availability: No HLA-identical, HLA-matched, partially HLA-mismatched, or HLA-haploidentical donor is available
      • Other malignancy or immunodeficiency: No other malignancy or significant immunodeficiency disorder is present
      • Viral infection: No active, uncontrolled hepatitis C virus (HCV) or hepatitis B virus (HBV) infection is present
    • Prescriber: The medication is prescribed by or in consultation with a hematologist/oncologist
    • Administration: Omisirge (omidubicel-onlv) is administered as a one-time infusionone-time infusion

    Severe Aplastic Anemia

    Omisirge may be considered medically necessary for severe aplastic anemia when ALL of the following criteria are met:

    Severe aplastic anemia criteria

    • Age: The individual is aged 6 years or older6 years or older
    • Diagnosis: The individual has a diagnosis of severe aplastic anemia
    • Donor availability: No HLA-identical donor is available
    • Conditioning: Omisirge (omidubicel-onlv) will be administered following reduced-intensity conditioning

    Uses of Omisirge (omidubicel-onlv) for conditions not outlined in this policy are considered investigational.

    Repeat treatment with Omisirge (omidubicel-onlv) is considered investigational; re-authorization is not covered under this policy.

    Omisirge is contraindicated for individuals with known sensitivity to dimethyl sulfoxide (DMSO), Dextran 40, gentamicin, human serum albumin, or bovine material.

    HCPCS and Product Specifications

    HCPCSHCPCSCovered
    J3406Injection, Omidubicel-onlv, (Omisirge), per therapeutic dose (new code effective 10/01/26)
    Added HCPCS CodeHCPCS
    J3406HCPCS code added for Omisirge
    Removed HCPCS CodesHCPCS
    C9399HCPCS code removed for Omisirge
    J3590HCPCS code removed for Omisirge
    Cultured Fraction total viable cells
    FractionCultured Fraction (CF)
    Minimum total viable cells8.0 x 10^8 total viable cells
    Dose contextThe single dose of Omisirge consists of a Cultured Fraction and a Non-cultured Fraction.
    Cultured Fraction CD34+ cells
    FractionCultured Fraction (CF)
    Minimum CD34+ percentage8.7% CD34+ cells
    Minimum CD34+ cell count

    Authorization and Documentation Requirements

    Prior Authorization

    Hematologic Malignancy Authorization

    Prior authorization is required. Omisirge (omidubicel-onlv) may be medically necessary for hematologic malignancies when all applicable criteria are met.

    • Individual is aged 12 years or older.
    • Has a hematologic malignancy and is planned for umbilical cord blood transplantation following myeloablative conditioning to reduce time to neutrophil recovery and the incidence of infection.
    • Is a candidate for myeloablative allogeneic hematopoietic stem cell transplantation (HSCT).
    • Has no available HLA-identical, HLA-matched, partially HLA-mismatched, or HLA-haploidentical donor.
    • Has no other malignancy or significant immunodeficiency disorder and no active, uncontrolled HCV or HBV infection.
    • Medication is prescribed by or in consultation with a hematologist/oncologist.
    • Omisirge is administered as a one-time infusion.
    Prior Authorization

    Severe Aplastic Anemia Authorization

    Clinical Context

    Hematologic malignancies are cancers that arise in blood-forming tissues or cells of the immune system. Examples include leukemia, lymphoma, and multiple myeloma. In this policy, Omisirge is used to support transplantation in eligible individuals with hematologic malignancies, with the goal of reducing time to neutrophil recovery and infection incidence.

    Terms and Treatment Components

    Omisirge (omidubicel-onlv)
    TherapyA nicotinamide-modified allogeneic hematopoietic progenitor cell therapy
    SourceDerived from umbilical cord blood
    Indication contextIndicated for individuals 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.
    Myeloablative conditioning
    Conditioning approachMyeloablative conditioning
    Treatment relationshipRequired before planned umbilical cord blood transplantation for the hematologic malignancy indication.

    Initial Therapy

    Hematologic Malignancy — Initial Therapy

    Omisirge may be considered medically necessary for initial treatment of hematologic malignancies when ALL of the following criteria are met:

    Hematologic malignancy initial therapy

    • Age: The individual is aged 12 years or older12 years or older
    • Diagnosis and transplant plan: The individual has a diagnosis of a hematologic malignancy and is planned for umbilical cord blood transplantation following myeloablative conditioning to reduce both time to neutrophil recovery and the incidence of infection
    • Transplant candidacy: The individual is a candidate for myeloablative allogeneic hematopoietic stem cell transplantation (HSCT)

    Reauthorization and Repeat Treatment

    Repeat Treatment

    Re-authorization is not available for repeat treatment.

    Repeat treatment: Re-authorization of repeat treatment with Omisirge (omidubicel-onlv) is considered investigational

    Repeat treatment is not covered under this policy; the dosing limit is one intravenous infusion per lifetime.

    Lifetime Dose Limit

    Omisirge (omidubicel-onlv)
    ProductOmisirge (omidubicel-onlv)
    Quantity limitOne intravenous infusion
    Lifetime limitOne infusion per lifetime
    Policy Summary
    PayerPremera Bluecross
    PolicyOmisirge (omidubicel-onlv) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOctober 1, 2026
    Last ReviewApr 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior-authorization documentation confirming that the applicable medical-necessity criteria are met.
    SourceLink
    On This Page
    Covered and Investigational UsesHCPCS and Product SpecificationsAuthorization and Documentation RequirementsClinical ContextTerms and Treatment ComponentsInitial TherapyReauthorization and Repeat TreatmentLifetime Dose Limit
    reduced-intensity conditioning
  1. Prescriber: The medication is prescribed by or in consultation with a hematologist/oncologist
  2. Administration: Omisirge (omidubicel-onlv) is administered as a one-time infusionone-time infusion
  3. 9.2 x 10^7 CD34+ cells
    Non-cultured Fraction total viable cells
    FractionNon-cultured Fraction (NF)
    Minimum total viable cells4.0 x 10^8 total viable cells
    Dose contextThe Non-cultured Fraction is part of each single dose of Omisirge.
    Non-cultured Fraction CD3+ cells
    FractionNon-cultured Fraction (NF)
    Cell typeCD3+ cells
    Minimum cell count2.4 x 10^7 CD3+ cells

    Prior authorization is required. Omisirge (omidubicel-onlv) may be medically necessary for severe aplastic anemia when all applicable criteria are met.

    • Individual is aged 6 years or older.
    • Has a diagnosis of severe aplastic anemia.
    • Does not have an available HLA-identical donor.
    • Omisirge is administered following reduced-intensity conditioning.
    • Medication is prescribed by or in consultation with a hematologist/oncologist.
    • Omisirge is administered as a one-time infusion.
    Documentation Required

    Hematologic Malignancy Records

    Submit medical records demonstrating that medical-necessity criteria are met for hematologic malignancy treatment with Omisirge.

    • Age 12 years or older.
    • Diagnosis of a hematologic malignancy.
    • No available HLA-identical, HLA-matched, HLA-mismatched, or HLA-haploidentical donor.
    • No history of prior gene therapy or allogeneic hematopoietic stem cell transplant.
    • No other malignancy or significant immunodeficiency disorder.
    • No active, uncontrolled hepatitis C virus (HCV) or hepatitis B virus (HBV) infection.
    Documentation Required

    Severe Aplastic Anemia Records

    Submit medical records demonstrating that medical-necessity criteria are met for severe aplastic anemia treatment with Omisirge.

    • Age 6 years or older.
    • Diagnosis of severe aplastic anemia.
    • No available HLA-identical donor.
    • Administration following reduced-intensity conditioning.
    • Prescription by or consultation with a hematologist/oncologist.
    • Planned one-time infusion.
    Denial Risk

    Unlisted Indications

    All other uses of Omisirge (omidubicel-onlv) for conditions not outlined in this policy are considered investigational.

    • Use must follow the product's U.S. Food and Drug Administration (FDA) dosage and administration prescribing information.
    Denial Risk

    Repeat Treatment

    Repeat treatment with Omisirge (omidubicel-onlv) is considered investigational and is not eligible for coverage under this policy.

    • Initial authorization is limited to a one-time infusion.
    • Re-authorization for repeat treatment is considered investigational.
    Denial Risk

    Disqualifying Clinical or Donor Factors

    Coverage for hematologic malignancies is not available when any disqualifying clinical or donor factor is present.

    • An HLA-identical, HLA-matched, partially HLA-mismatched, or HLA-haploidentical donor is available.
    • The individual has another malignancy or significant immunodeficiency disorder.
    • The individual has an active, uncontrolled HCV or HBV infection.
    • The individual has a history of prior gene therapy or allogeneic hematopoietic stem cell transplant.
    Denial Risk

    HLA-Identical Donor Availability

    For severe aplastic anemia, documentation must establish that no HLA-identical donor is available before Omisirge can be considered for coverage.

    • An available HLA-identical donor disqualifies the individual from severe aplastic anemia coverage under this policy.
    Denial Risk

    Product Sensitivity

    Omisirge is contraindicated in individuals with known sensitivity to any listed product component; verify sensitivities before administration to reduce denial and safety risk.

    • Dimethyl sulfoxide (DMSO).
    • Dextran 40.
    • Gentamicin.
    • Human serum albumin.
    • Bovine material.
    Clinical contextUsed when the individual is a candidate for myeloablative allogeneic hematopoietic stem cell transplantation.
    Reduced-intensity conditioning
    Conditioning approachReduced-intensity conditioning
    Treatment relationshipRequired for Omisirge use in severe aplastic anemia.
    Administration contextOmisirge is administered following reduced-intensity conditioning.
  4. Required absence of exclusions

    • Donor availability: No HLA-identical, HLA-matched, partially HLA-mismatched, or HLA-haploidentical donor is available
    • Other malignancy or immunodeficiency: No other malignancy or significant immunodeficiency disorder is present
    • Viral infection: No active, uncontrolled hepatitis C virus (HCV) or hepatitis B virus (HBV) infection is present
  5. Prescriber: The medication is prescribed by or in consultation with a hematologist/oncologist
  6. Administration: Omisirge (omidubicel-onlv) is administered as a one-time infusionone-time infusion
  7. Severe Aplastic Anemia — Initial Therapy

    Omisirge may be considered medically necessary for initial treatment of severe aplastic anemia when ALL of the following criteria are met:

    Severe aplastic anemia initial therapy

    • Age: The individual is aged 6 years or older6 years or older
    • Diagnosis: The individual has a diagnosis of severe aplastic anemia
    • Donor availability: No HLA-identical donor is available
    • Conditioning: Omisirge (omidubicel-onlv) will be administered following reduced-intensity conditioningreduced-intensity conditioning
    • Prescriber: The medication is prescribed by or in consultation with a hematologist/oncologist
    • Administration: Omisirge (omidubicel-onlv) is administered as a one-time infusionone-time infusion